Gastric Cancer

P2, N=100, Recruiting, Jeeyun Lee | N=50 --> 100

P2, N=2, Active, not recruiting, National Cancer Institute (NCI) | N=240 --> 2 | Trial completion date: Oct 2027 --> Jun 2027 | Trial primary completion date: Oct 2027 --> Jan 2026

P=N/A, N=150, Recruiting, Harbin Medical University | Not yet recruiting --> Recruiting

Through a comprehensive and systematic search of the best available evidence, the Neoplastic Diseases Task Force developed 20 recommendations on screening and risk factor assessment for 10 specific questions on neoplastic diseases. These recommendations serve as guidance on screening neoplastic diseases at the primary care level.

Together, these findings suggest that cagA-positive H. pylori infection is associated with Fn14 upregulation, whereas H. pylori infection in general is linked to TNFR2 downregulation. IL-13-related signaling may instead reflect mucosal injury and repair responses, indicating context-dependent regulation of TNF receptor family pathways in gastric mucosal inflammation.

Future directions include prospective multicenter validation in clinical workflows, standardization of evaluation frameworks, and implementation of uncertainty estimation to support clinical decision-making. Overall, AI-enabled digital pathology represents a promising approach for advancing precision oncology in GC by improving biomarker assessment and providing insights into tumor biology.

Our study identifies a spatially organized niche involving CSF1+malignant cells and SPP1+ macrophages as a key driver of ICB resistance in GC. By defining the CSF1-mediated crosstalk between these two cell types, these findings highlight promising therapeutic targets to enhance the efficacy of immunotherapy.

Our findings support a mitochondrial conserved gene expression homeostasis imbalance in GC, which is characterized by compartment-specific mtGene expression imbalance. Also, KRT7 and KLRC1 emerge as prognostic markers for therapies aimed at restoring mitochondrial homeostasis in GC.

The anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) monoclonal antibody ramucirumab was the first antiangiogenic agent approved for HER2-negative metastatic gastric adenocarcinomas and remains a standard second-line treatment either alone or in combination with paclitaxel. Other VEGFR-targeting agents, such as the tyrosine kinase inhibitors (TKI) regorafenib and apatinib, have failed to demonstrate any survival benefit in the first-line settings, while providing modest improvements in pretreated patients, even when combined with Immune Checkpoint Inhibitors (ICI)...Although several biomarker candidates have been explored, reliable predictors are still awaited. This review summarizes current evidence and explores the future of antiangiogenic agents in gastric cancers.

Particular attention is given to HER2-directed antibody-drug conjugates, especially trastuzumab deruxtecan (T-DXd), which have emerged as an important recent therapeutic advance and have renewed interest in HER2 as an actionable target in selected patients with HER2-expressing cervical carcinoma. This review further highlights the need for biomarker-driven patient selection, standardized HER2 assessment, and rational integration of HER2-directed strategies into precision treatment for CC.

PCA-derived perioperative inflammatory phenotypes effectively stratify recurrence risk in LAGC. The "Dual-High" phenotype indicates poor prognosis, and combining these phenotypes with T stage, N stage, and preoperative CEA enhances individualized postoperative surveillance and adjuvant therapy decision-making.

In summary, our work highlights the critical role of the CD90-IGF2BP2-CD47 axis in immune evasion in GC. This finding is expected to provide significant experimental evidence for elucidating the pathogenesis of GC and discovering potential molecular targets for clinical treatment.